NASDAQ:BPTH

Bio-Path - BPTH Stock Forecast, Price & News

$3.18

-0.30 (-8.62%)

(As of 09/23/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.10
▼
$3.58
50-Day Range: $3.18
▼
$4.18
52-Week Range: $2.68
▼
$5.41

Volume: 118,043 shs
Average Volume: 12,680 shs
Market Capitalization: $22.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.00

Bio-Path MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 183.0% Upside
$9.00 Price Target
Short Interest: Healthy
2.49% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.19
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.76) to ($1.61) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

442nd out of 1,075 stocks

Pharmaceutical Preparations Industry

205th out of 532 stocks

3.5

Analyst's Opinion

Consensus Rating
Bio-Path has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.00, Bio-Path has a forecasted upside of 183.0% from its current price of $3.18.
Amount of Analyst Coverage
Bio-Path has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.49% of the float of Bio-Path has been sold short.
Short Interest Ratio / Days to Cover
Bio-Path has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Bio-Path has recently decreased by 11.02%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Bio-Path does not currently pay a dividend.
Dividend Growth
Bio-Path does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BPTH.

1.2

News and Social Media Coverage

News Sentiment
Bio-Path has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Bio-Path this week, compared to 4 articles on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bio-Path insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.28% of the stock of Bio-Path is held by insiders.
Percentage Held by Institutions
Only 5.76% of the stock of Bio-Path is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Bio-Path are expected to grow in the coming year, from ($1.76) to ($1.61) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bio-Path is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bio-Path is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bio-Path has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Bio-Path (NASDAQ:BPTH) Stock

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Receive BPTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.

BPTH Stock News Headlines

September 20, 2022 | americanbankingnews.com

Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com

September 16, 2022 | benzinga.com

J INTS BIO's Novel Oral 4th Generation EGFR-TKI 'JIN-A02' effective against both cis and trans isomers of C797S mutations - ESMO 2022 - Benzinga

September 16, 2022 | benzinga.com

Palisade Bio (NASDAQ:PALI) – Palisade Bio Streamlines Operations and Identifies Capital Efficiencies to F - Benzinga

September 15, 2022 | benzinga.com

Contract Injectable Packaging Trends in the Bio/Pharma Industry - Benzinga

September 12, 2022 | benzinga.com

Indonesia's Bio Farma ready to produce 'IndoVac' Covid-19 vaccines - Benzinga

September 10, 2022 | finance.yahoo.com

Indonesian Pharmaceutical PT Bio Farma Ready to Mass Produce IndoVac Covid-19 Vaccines - Yahoo Finance

September 9, 2022 | businesswire.com

Global Cardiac Markers Rapid Tests and POC Pipeline Report 2022 - Featuring 1Drop Diagnostics, Abbott Point of Care and Accel Diagnostics Among Others - ResearchAndMarkets.com - Business Wire

September 9, 2022 | benzinga.com

Indonesian pharmaceutical Bio Farma ready to produce IndoVac Covid-19 vaccines - Benzinga

September 8, 2022 | finance.yahoo.com

Chardan Announces the Inaugural SPICI (Smart People in Cellular Immunotherapy) Symposium - Yahoo Finance

September 8, 2022 | fool.com

Bioceres Crop Solutions Corp. (BIOX) Q4 2022 Earnings Call Transcript - The Motley Fool

September 8, 2022 | nasdaq.com

Why Is Karuna Therapeutics, Inc. (KRTX) Up 8.4% Since Last Earnings Report? - Nasdaq

September 7, 2022 | businesswire.com

2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients - Business Wire

September 6, 2022 | finance.yahoo.com

Business Intelligence Group Awards BioHarvest Sciences with the Prestigious Sustainability Leadership Award - Yahoo Finance

September 6, 2022 | benzinga.com

Bio-Path Holdings (BPTH) – Bio-Path Holdings to Present at H.C. Wainwright 24th Annual Global Investment - Benzinga

September 6, 2022 | finance.yahoo.com

Bio-Path Holdings to Present at H.C. Wainwright 24th Annual Global Investment Conference

September 5, 2022 | streetinsider.com

South Korea's CD BIO Seeks Clinical Trial, FDA Registration for Its VOCs Biosensing Kit That Detects Early Stage Lung and Other Cancers With Simple Breathing Test - StreetInsider.com

September 5, 2022 | finance.yahoo.com

South Korea's CD BIO Seeks Clinical Trial, FDA Registration for Its VOCs Biosensing Kit That Detects Early Stage Lung and Other Cancers With Simple Breathing Test - Yahoo Finance

August 25, 2022 | benzinga.com

Aeglea Bio Feels FDA Refusal Pinch, Cuts Workforce, Shifts Pipeline Focus - Benzinga

August 24, 2022 | globenewswire.com

Bio Plasticizers Market to Gain Significantly from Automotive Applications, Asian Markets Poised to Flourish - GlobeNewswire

August 17, 2022 | bloomberg.com

Bluebird's Game-Changing Therapy for Rare Blood Disorder Cleared by FDA - Bloomberg

August 16, 2022 | investing.com

Bio-Path Holdings Tops Q2 EPS by 8c By Investing.com - Investing.com

August 16, 2022 | finance.yahoo.com

Bio-Path Holdings Reports Second Quarter 2022 Financial Results

August 15, 2022 | finance.yahoo.com

Tarsier Pharma announces development of TRS02, a potential immunomodulator, for the treatment of retinal diseases with sustained-release intravitreal formulation - Yahoo Finance

August 12, 2022 | bloomberg.com

Inotiv, Inc. Announces Third Quarter Fiscal 2022 Financial Results - Bloomberg

August 10, 2022 | benzinga.com

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans - Benzinga

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BPTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.

BPTH Company Calendar

Last Earnings: 8/16/2022
Today: 9/25/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BPTH
CUSIP: N/A
CIK: 1133818
Web: www.biopathholdings.com
Phone: (832) 742-1357
Fax: N/A
Employees: 10
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.00
High Stock Price Forecast: $9.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +183.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.77)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,440,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -51.96%
Return on Assets: -49.06%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.57
Quick Ratio: 15.57

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.56 per share
Price / Book: 0.89

Miscellaneous

Outstanding Shares: 7,160,000
Free Float: 6,997,000
Market Cap: $22.77 million
Optionable: Not Optionable
Beta: 1.45

Key Executives

Mr. Peter H. Nielsen MBA (Age 73)
Co-Founder, Chairman, CEO, Pres, CFO & Treasurer
Comp: $680.18k

Mr. Douglas P. Morris (Age 66)
Co-Founder, Director of Investor Relations, Sec. & Director
Comp: $68.47k

Mr. Anthony Price
Sr. VP of Fin., Accounting & Admin.

Dr. Ana Tari Ashizawa Ph.D.
MBA, Sr. VP of Research, Devel. & Clinical Design

Dr. Alan MacKenzie Ph.D.
Consultant

Dr. Thomas A. Walker Ph.D.
Consultant

Dr. Jeffery Lancet M.D.
Consultant

Ms. Victoria Lake Rac
Regulatory Consultant

Key Competitors

View All Competitors

Insiders & Institutions

Renaissance Technologies LLC
Bought 18,000 shares on 8/13/2022
Ownership: 0.251%

View All Insider Transactions
View All Institutional Transactions

BPTH Stock - Frequently Asked Questions

Should I buy or sell Bio-Path stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BPTH shares.
View BPTH analyst ratings or view top-rated stocks.
What is Bio-Path's stock price forecast for 2022?: 1 Wall Street research analysts have issued 12-month price objectives for Bio-Path's shares. Their BPTH share price forecasts range from $9.00 to $9.00. On average, they anticipate the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 183.0% from the stock's current price.
View analysts price targets for BPTH or view top-rated stocks among Wall Street analysts.
How have BPTH shares performed in 2022?: Bio-Path's stock was trading at $3.77 on January 1st, 2022. Since then, BPTH shares have decreased by 15.6% and is now trading at $3.18.
View the best growth stocks for 2022 here.
When is Bio-Path's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our BPTH earnings forecast.
How were Bio-Path's earnings last quarter?: Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced its earnings results on Tuesday, August, 16th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.08. During the same period last year, the firm posted ($0.26) earnings per share.
When did Bio-Path's stock split?: Bio-Path shares reverse split before market open on Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 17th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Bio-Path own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC).
What is Bio-Path's stock symbol?: Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."
Who are Bio-Path's major shareholders?: Bio-Path's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.25%).
View institutional ownership trends.
How do I buy shares of Bio-Path?: Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Bio-Path's stock price today?: One share of BPTH stock can currently be purchased for approximately $3.18.
How much money does Bio-Path make?: Bio-Path (NASDAQ:BPTH) has a market capitalization of $22.77 million. The company earns $-10,440,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis.
How can I contact Bio-Path?: Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The official website for the company is www.biopathholdings.com. The company can be reached via phone at (832) 742-1357 or via email at will@sternir.com.

This page (NASDAQ:BPTH) was last updated on 9/25/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial Subscription Here

Bio-Path - BPTH Stock Forecast, Price & News

Bio-Path MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month